483 Roundup: FDA Cites Five Firms for Quality, Other Violations

Drug GMP Report
The FDA flagged four U.S. facilities and one in Switzerland for quality and other violations observed during agency inspections—from inadequate testing to incomplete records.

To View This Article:


Subscribe To Drug GMP Report

Buy This Article Now

Add this article to your cart for $200.00